The protonation state of the catalytic aspartates of HIV-1 protease (HIVPR) is atypical and as a result is the subject of much debate. Modeling of the correct protonation state of the aspartates is vital in computational drug design. Using pH replica-exchange molecular dynamics, we simulated the apo and bound forms of HIV-1 protease with 12 different protease inhibitors to investigate the p<i>K</i><sub>a</sub> of not only the catalytic dyad but also the other titrating residues in HIVPR. The results obtained from these simulations are compared to experiment where possible. This study provides evidence that the catalytic aspartates are primarily in a monoprotonated state for both the apo and bound forms of HIVPR in the pH range where general...
HIV-1 aspartic protease (PR) is a promising target for acquired immunodeficiency syndrome (AIDS) the...
Despite a large number of antiretroviral drugs targeting HIV-1 protease for inhibition, mutations in...
AbstractPlasmepsin IV (PM IV) is a potential target for developing drugs against malaria. This Lette...
AbstractThe data described here supports the research article “Unraveling HIV Protease Flaps Dynamic...
The data described here supports the research article “Unraveling HIV Protease Flaps Dynamics by Con...
Chemical synthesis was used to prepare the HIV-1 protease specifically 13C-labelled in the catalytic...
HIV-1 protease is most active under weakly acidic conditions (pH 3.5-6.5), when the catalytic Asp25 ...
HIV-1 protease is most active under weakly acidic conditions (pH 3.5-6.5), when the catalytic Asp25 ...
AbstractThe mechanism of the first steps of the reaction catalyzed by HIV-1 protease was studied thr...
AbstractAssigning the correct protonation state to the catalytic residues is essential for a realist...
ABSTRACT HIV-1 protease is most active un-der weakly acidic conditions (pH 3.5–6.5), when the cataly...
AbstractThe active sites of 3 types of aspartic proteases are modeled, based on crystallographic coo...
Despite of a large number of antiretroviral drugs targeting HIV-1 protease for inhibition, mutations...
Despite of a large number of antiretroviral drugs targeting HIV-1 protease for inhibition, mutations...
Despite a large number of antiretroviral drugs targeting HIV-1 protease for inhibition, mutations in...
HIV-1 aspartic protease (PR) is a promising target for acquired immunodeficiency syndrome (AIDS) the...
Despite a large number of antiretroviral drugs targeting HIV-1 protease for inhibition, mutations in...
AbstractPlasmepsin IV (PM IV) is a potential target for developing drugs against malaria. This Lette...
AbstractThe data described here supports the research article “Unraveling HIV Protease Flaps Dynamic...
The data described here supports the research article “Unraveling HIV Protease Flaps Dynamics by Con...
Chemical synthesis was used to prepare the HIV-1 protease specifically 13C-labelled in the catalytic...
HIV-1 protease is most active under weakly acidic conditions (pH 3.5-6.5), when the catalytic Asp25 ...
HIV-1 protease is most active under weakly acidic conditions (pH 3.5-6.5), when the catalytic Asp25 ...
AbstractThe mechanism of the first steps of the reaction catalyzed by HIV-1 protease was studied thr...
AbstractAssigning the correct protonation state to the catalytic residues is essential for a realist...
ABSTRACT HIV-1 protease is most active un-der weakly acidic conditions (pH 3.5–6.5), when the cataly...
AbstractThe active sites of 3 types of aspartic proteases are modeled, based on crystallographic coo...
Despite of a large number of antiretroviral drugs targeting HIV-1 protease for inhibition, mutations...
Despite of a large number of antiretroviral drugs targeting HIV-1 protease for inhibition, mutations...
Despite a large number of antiretroviral drugs targeting HIV-1 protease for inhibition, mutations in...
HIV-1 aspartic protease (PR) is a promising target for acquired immunodeficiency syndrome (AIDS) the...
Despite a large number of antiretroviral drugs targeting HIV-1 protease for inhibition, mutations in...
AbstractPlasmepsin IV (PM IV) is a potential target for developing drugs against malaria. This Lette...